WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc., today presented encouraging preclinical data for its lead drug candidate, TP-434, which showed the potent antibacterial activity of TP-434 against a very broad spectrum of susceptible and multidrug-resistant pathogens. The data supported the utility of TP-434 as a once-daily monotherapy for serious infections. Data on TP-434, as well as data for another drug candidate, TP-271, from Tetraphase’s antibiotics product portfolio, were presented in 10 poster presentations at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) annual meeting in Boston, MA, being held September 12 -15. Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics.
